睿知中国疾病研究地图
候选清单0

北京首都医科大学

首都医科大学附属北京儿童医院

Beijing Children's Hospital

在本站收录的 53 种疾病中,这家医院列在其中 29 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

首都医科大学附属北京儿童医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝母细胞瘤Hepatoblastoma4 篇牵头论文
  2. 视网膜母细胞瘤Retinoblastoma6 篇牵头论文
  3. 骨肉瘤Osteosarcoma5 篇牵头论文
  4. 神经母细胞瘤Neuroblastoma33 篇牵头论文牵头 1 项开放试验
  5. 尤文肉瘤Ewing sarcoma4 篇牵头论文
  6. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia4 篇牵头论文
  7. 再生障碍性贫血Aplastic anaemia9 篇牵头论文
  8. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis31 篇牵头论文牵头 1 项开放试验
  9. β 地中海贫血Beta thalassaemia1 篇牵头论文
  10. 血友病 AHaemophilia A32 篇牵头论文
  11. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome2 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
  13. 范可尼贫血Fanconi anaemia1 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
  15. 烟雾病Moyamoya disease2 篇牵头论文
  16. 胆道闭锁Biliary atresia15 篇牵头论文
  17. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis4 篇牵头论文
  18. 大动脉炎Takayasu arteritis3 篇牵头论文
  19. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  20. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  21. 法布雷病Fabry disease0 篇牵头论文
  22. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  23. 白塞病Behçet disease1 篇牵头论文
  24. Alport 综合征Alport syndrome1 篇牵头论文
  25. IgA 肾病IgA nephropathy7 篇牵头论文
  26. 戈谢病Gaucher disease0 篇牵头论文
  27. 先天性巨结肠Hirschsprung disease13 篇牵头论文
  28. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa1 篇牵头论文
  29. Majeed 综合征Majeed syndrome0 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、脊索瘤、胃肠道间质瘤、多发性骨髓瘤、IgG4相关性疾病、重症肌无力、肝豆状核变性、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、庞贝病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.6%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 3320232024: 1120242025: 002025

北京有 9 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.0%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 3320232024: 0020242025: 002025

北京有 10 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科肿瘤内科儿科眼科/神经眼科
牵头的论文6
  1. Incidental detection of retinoblastoma from accidental trauma in children.2023BMC ophthalmology
  2. Clinical characteristics, treatment and prognosis of infants with retinoblastoma: a multicenter, 10-year retrospective analysis.2023BMC pediatrics
  3. The survival analysis and feasibility study of Pars Plana Vitrectomy (PPV) in the treatment of retinoblastoma.2023Journal of cancer research and clinical oncology
  4. Spectrum and tissue distribution of RB1 pathogenic alleles in mosaic retinoblastoma patients.2022Ophthalmic genetics
  5. Clinical Features and Survival of Chinese Children With Trilateral Retinoblastoma During 2006-2019: A Retrospective Multicenter Study.2021American journal of ophthalmology
  6. RB1 germline mutation spectrum and clinical features in patients with unilateral retinoblastomas.2021Ophthalmic genetics
早期论文(2016–2020 年)6
  1. Retinoblastoma in a child with tuberous sclerosis complex.2020Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  2. Economic burden for retinoblastoma patients in China.2020Journal of medical economics
  3. Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma.2020Ophthalmology. Retina
  4. Reply.2018Ophthalmology
  5. Pars Plana Vitrectomy and Endoresection of Refractory Intraocular Retinoblastoma.2018Ophthalmology
  6. [The key points in intravenous chemotherapy and intra-arterial chemotherapy on retinoblastoma treatment].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma状态不明NCT04990271研究中心II期2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 2220242025: 002025

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科耳鼻喉/头颈外科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 33 篇,占 2.9%。

牵头论文
33
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 4420222023: 9920232024: 4420242025: 882025

北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
    分期
    不分期
    开始
    2024-06
    登记号
    NCT06818916

    年龄 未注明 至 18 岁(登记的条件)

    牵头:首都医科大学附属北京儿童医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科儿科病理/检验科神经内科
牵头的论文33
  1. Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN.2026Cancer biology & therapy
  2. A Primary Report 166 Cases of Abdominal or Pelvic Neuroblastoma Surgery Utilizing the International Neuroblastoma Surgical Report Form (INSRF).2025Annals of surgery
  3. The changes of immune function after neuroblastoma chemotherapy and the prediction of potential immune targets.2025BMC medical genomics
  4. Causal links between congenital malformations, birth weight, and neuroblastoma: insights from Mendelian randomization.2025BMC pediatrics
  5. Genetic insights into neuroblastoma: the role of immune cell features.2025Cytokine
  6. Development of a Predictive Model Based on Ultrasonographic Characteristics to Distinguish Neonatal Adrenal Cystic Neuroblastoma From Hematoma.2025Journal of clinical ultrasound : JCU
  7. The causal relationship between immune cells and neuroblastoma: a Mendelian randomization study.2025Molecular neurobiology
  8. Aberrant serum lipid levels predict clinical outcomes in patients with neuroblastoma.2025Pediatric hematology and oncology
  9. Risk factors and predictive thresholds for postoperative pleural effusion in children with neuroblastoma: a retrospective cohort study.2025World journal of surgical oncology
  10. Risk factors, impact and treatment of postoperative lymphatic leakage in children with abdominal neuroblastoma operated on by laparotomy.2024BMC surgery
  11. Therapeutic SHPRH-146aa encoded by circ-SHPRH dynamically upregulates P21 to inhibit CDKs in neuroblastoma.2024Cancer letters
  12. Renal preservation in high-risk retroperitoneal neuroblastoma: Impact on survival and local progression.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood.2024Neurology(R) neuroimmunology & neuroinflammation
  14. Nectin2 influences cell apoptosis by regulating ANXA2 expression in neuroblastoma.2023Acta biochimica et biophysica Sinica
  15. Clinical and molecular epidemiologic features of enterovirus D68 infection in children with acute lower respiratory tract infection in China.2023Archives of virology
  16. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.2023Cancer science
  17. Elevated exosome-transferrable lncRNA EPB41L4A-AS1 in CD56bright NK cells is responsible for the impaired NK function in neuroblastoma patients by suppressing cell glycolysis.2023Clinical immunology (Orlando, Fla.)
  18. Synchronous Hepatoblastoma and Neuroblastoma in Two Chinese Infants.2023Fetal and pediatric pathology
  19. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.2023Journal of molecular medicine (Berlin, Germany)
  20. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.2023Pediatric blood & cancer
  21. Translational practice of fluorescence in situ hybridisation to identify neuroblastic tumours with TERT rearrangements.2023The journal of pathology. Clinical research
  22. Safety and feasibility of laparoscopic resection of abdominal neuroblastoma without image-defined risk factors: a single-center experience.2023World journal of surgical oncology
  23. MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.2022Cancer medicine
  24. The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma.2022Immunology letters
  25. Clinical and surgical outcome differences on the basis of pathology category in cervical neuroblastic tumors.2022Journal of pediatric surgery
  26. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.2022Pediatric hematology and oncology
  27. Mesenchymal stem cells accelerated growth and metastasis of neuroblastoma and preferentially homed towards both primary and metastatic loci in orthotopic neuroblastoma model.2021BMC cancer
  28. Biological features and clinical outcome in infant neuroblastoma: a multicenter experience in Beijing.2021European journal of pediatrics
  29. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.2021Italian journal of pediatrics
  30. The development and initial evaluation of referral flowchart for suspected neuroblastoma for pediatricians in nononcology clinics in China.2021Pediatric blood & cancer
  31. Coexistence of orbital rhabdomyosarcoma and adrenal neuroblastic tumor in a child.2021Pediatrics international : official journal of the Japan Pediatric Society
  32. Primary renal ganglioneuroblastoma mimicking Wilms' tumor in a 3-year-old girl.2021Pediatrics international : official journal of the Japan Pediatric Society
  33. MYC-associated protein X binding with the variant rs72780850 in RNA helicase DEAD box 1 for susceptibility to neuroblastoma.2021Science China. Life sciences
中文论文(未计入)6
  1. [Role and mechanism of cysteine and glycine-rich protein 2 in the malignant progression of neuroblastoma].2024Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  2. [Clinical and prognostic analysis of opsoclonus-myoclonus-ataxia syndrome in children].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. [Research progresses of tumor associated macrophages in neuroblastoma].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
  4. [Clinical characteristics and prognostic analyses of cervical neuroblastoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  5. [Research progress on the relationship between epigenetics and neuroblastoma in children].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  6. [Two cases of neuroblastoma in the triplets].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
早期论文(2016–2020 年)22
  1. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.2020Acta biochimica Polonica
  2. Clinical characteristics and risk factors of 47 cases with ruptured neuroblastoma in children.2020BMC cancer
  3. Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma.2020BMC cancer
  4. The increased IL-17-producing γδT cells promote tumor cell proliferation and migration in neuroblastoma.2020Clinical immunology (Orlando, Fla.)
  5. Analysis of treatment cost for neuroblastoma to the family: a single-center cross-sectional study in China.2020Journal of medical economics
  6. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.2020Journal of neuroinflammation
  7. Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma: Two case reports.2020Medicine
  8. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.2020Molecular oncology
  9. Comprehensive Characterization of Circular RNAs in Neuroblastoma Cell Lines.2020Technology in cancer research & treatment
  10. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].2020Zhonghua er ke za zhi = Chinese journal of pediatrics
  11. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.2019Cancer communications (London, England)
  12. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma.2019Cancer medicine
  13. Diminished cytolytic activity of γδ T cells with reduced DNAM-1 expression in neuroblastoma patients.2019Clinical immunology (Orlando, Fla.)
  14. lncRNA SNHG16 is associated with proliferation and poor prognosis of pediatric neuroblastoma.2019International journal of oncology
  15. IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.2019Pediatric research
  16. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].2019Zhonghua er ke za zhi = Chinese journal of pediatrics
  17. Serum Interleukin-6 Level and the rs1800795 Polymorphism in its Gene Associated with Neuroblastoma Risk in Chinese Children.2018Chinese medical journal
  18. Discrimination of histopathologic types of childhood peripheral neuroblastic tumors based on clinical and biological factors.2018Scientific reports
  19. γδTFH cells promote B cell maturation and antibody production in neuroblastoma.2017BMC immunology
  20. Role of diffusion-weighted imaging in distinguishing thoracoabdominal neuroblastic tumours of various histological types and differentiation grades.2017Journal of medical imaging and radiation oncology
  21. Maternal smoking during pregnancy and risk of childhood neuroblastoma: Systematic review and meta-analysis.2016Journal of cancer research and therapeutics
  22. Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma正在招募NCT06818916牵头方不分期2024-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
    分期
    II期
    开始
    2024-09
    登记号
    NCT06564272

    年龄 12 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科耳鼻喉/头颈外科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

北京有 10 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    分期
    II期
    开始
    2022-01
    登记号
    NCT05334823

    年龄 3 岁 至 21 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、苏州、郑州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童费城染色体与遗传学副作用(细胞因子释放综合征、神经毒性)

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 9 篇,占 2.2%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 1120232024: 2220242025: 222025

北京有 6 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题儿童免疫抑制治疗干细胞移植
论文中的科室肿瘤内科
牵头的论文9
  1. A case of ADH5/ALDH2 deficiency combined with 3q29 microduplication syndrome.2025BMC pediatrics免费全文
  2. Eltrombopag combined with immunosuppressive therapy for pediatric severe aplastic anemia.2025Pediatric research
  3. Clinical characteristics of hepatitis-associated aplastic anemia in children.2024Annals of hematology
  4. Haploidentical hematopoietic stem cell transplantation as a first-line treatment for paediatric severe aplastic anemia: a single-center research.2024International journal of medical sciences免费全文
  5. Elevated TCR-αβ+ double-negative T cells in pediatric patients with acquired aplastic anemia.2023Clinica chimica acta; international journal of clinical chemistry
  6. Effect of Wuzhi capsules on cyclosporine A concentration in children with aplastic anemia immunotherapy: a single-center observational study.2022Expert review of clinical pharmacology
  7. Immune Reconstitution in Pediatric Aplastic Anemia after Allogeneic Hematopoietic Stem-cell Transplantation.2022International journal of medical sciences免费全文
  8. Efficacy of hematopoietic stem cell transplantation in the treatment of children with non-severe aplastic anemia.2022Pediatric transplantation
  9. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.2021Pediatric hematology and oncology
中文论文(未计入)3
  1. [Prognostic factors of immunosuppression therapy combined with eltrombopag in the treatment of childhood severe aplastic anemia].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Three cases of aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. [Progress in pathogenesis of bone marrow failure in Fanconi anemia].2022Zhonghua er ke za zhi = Chinese journal of pediatrics

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 31 篇,占 7.8%。

牵头论文
31
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 9920222023: 7720232024: 7720242025: 442025

北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
    分期
    不分期
    开始
    2025-10
    登记号
    NCT07488728

    年龄 未注明 至 18 岁(登记的条件)

    牵头:首都医科大学附属北京儿童医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题儿童治疗方案遗传与家族性
论文中的科室儿科肿瘤内科
牵头的论文31
  1. Long-Term Outcomes of a Stratified Treatment Regimen Based on Etoposide and Glucocorticoids in Children With Hemophagocytic Lymphohistiocytosis (CCHG-HLH-2018): A Multicenter, Single-Arm Clinical Study.2026American journal of hematology
  2. Efficacy of emapalumab in treating 3 pediatric patients with epstein-barr virus-associated hemophagocytic lymphohistiocytosis complicated by multiple organ dysfunction.2025Annals of medicine免费全文
  3. Efficacy and safety of ruxolitinib-based regimen in the treatment of paediatric Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.2025British journal of haematology
  4. Hospitalization trends and clinical burden of paediatric haemophagocytic lymphohistiocytosis in a multicentre study in China.2025British journal of haematology
  5. Ruxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related haemophagocytic lymphohistiocytosis.2025British journal of haematology
  6. Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH).2024Annals of hematology
  7. Genetic and clinical characteristics of primary hemophagocytic lymphohistiocytosis in children.2024Annals of hematology
  8. Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis.2024Haematologica
  9. Biomarkers in Pediatric Hemophagocytic Lymphohistiocytosis With Central Nervous System Involvement: A Cohort Study.2024Journal of pediatric hematology/oncology
  10. Ruxolitinib Monotherapy for a Child With HAVCR2 Gene Mutation Associated Subcutaneous Panniculitis-like T-cell Lymphoma: A Case Report.2024Journal of pediatric hematology/oncology
  11. Familial Hemophagocytic Lymphohistiocytosis Type 2 Presenting With Isolated Facial Palsy.2024Journal of pediatric hematology/oncology
  12. Three pediatric cases of Staphylococcus aureus-associated hemophagocytic lymphohistiocytosis.2024Pediatrics and neonatology
  13. Serum cytokine pattern in children with hemophagocytic lymphohistiocytosis.2023Annals of hematology免费全文
  14. Efficacy of ruxolitinib for HAVCR2 mutation-associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children.2023British journal of haematology
  15. Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug-drug interactions.2023Cancer chemotherapy and pharmacology
  16. Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: a systematic review of 63 patients reported in the literature.2023Clinical and experimental medicine
  17. Clinical Significance of Plasma Soluble MICB in Children With EBV-associated Hemophagocytic Lymphohistiocytosis.2023Journal of pediatric hematology/oncology
  18. Epstein-Barr virus-positive diffuse large B-cell lymphoma onset as familial hemophagocytic lymphohistiocytosis in an infant.2023Pediatric blood & cancer
  19. Manifestations of B-cell expansion with NF-κB and T-cell anergy disease overlapping with hemophagocytic lymphohistiocytosis.2023Scandinavian journal of immunology
  20. Development and application of an LC-MS/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis.2022Analytical methods : advancing methods and applications
  21. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.2022Blood
  22. 18F-FDG PET/CT for Identifying the Potential Primary Diseases and Predicting Prognosis of Secondary Hemophagocytic Lymphohistiocytosis in Children.2022Contrast media & molecular imaging免费全文
  23. Significance of serum Th1/Th2 cytokine levels in underlying disease classification of childhood HLH.2022Cytokine
  24. NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis.2022Journal of hematology & oncology免费全文
  25. A retrospective study of 18 children with subcutaneous panniculitis-like T-cell lymphoma: multidrug combination chemotherapy or immunomodulatory therapy?2022Orphanet journal of rare diseases免费全文
  26. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.2022Orphanet journal of rare diseases免费全文
  27. Clinical significance of cerebrospinal fluid soluble CD25 in pediatric hemophagocytic lymphohistiocytosis with central nervous system involvement.2022Pediatric blood & cancer
  28. Familial hemophagocytic lymphohistiocytosis onset as central diabetes insipidus in a child.2022Pediatric blood & cancer
  29. Successful rescue of a lethal Griscelli syndrome type 2 presenting with neurological involvement and hemophagocytic lymphohistiocytosis: a case report.2021BMC pediatrics免费全文
  30. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.2021Haematologica免费全文
  31. Hemophagocytic Lymphohistiocytosis Associated with Histiocytic Necrotizing Lymphadenitis: A Clinical Study of 13 Children and Literature Review.2021The Journal of pediatrics
中文论文(未计入)8
  1. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Analysis of 9 cases of drug induced hypersensitivity syndrome related hemophagocytic lymphohistiocytosis].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. [Progress in the application of targeted monoclonal antibodies in children with hemophagocytic syndrome].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
  4. [Efficacy and safety of modified hemophagocytic lymphohistiocytosis 04 regimen in Beijing Children's Hospital].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. [Clinical and molecular characteristics of Streptococcus pneumoniae-associated hemophagocytic lymphohistiocytosis in children].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  6. [Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone+/-PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis].2022Zhonghua yi xue za zhi
  7. [Association between genotype and clinical phenotype in children with primary hemophagocytic lymphohistiocytosis].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
  8. [Hemophagocytic lymphohistiocytosis: update on pathogenesis, diagnosis, and treatment].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis正在招募NCT07488728牵头方不分期2025-10 启动
  2. Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE已完成NCT05001737研究中心III期2021-12 启动
PubMed 以外找到的论文(未计入)2
  1. Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis2022TigerPrints (Clemson University)论文
  2. PP329 [Infections » Other]: CLINICAL CHARATERISTICS OF STREPTOCOCCUS PNEUMONIAE-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN WITH MOLECULAR FETURES OF STREPTOCOCCUS PNEUMONIAE2022Pediatric Critical Care Medicine会议摘要

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 10 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
牵头的论文1
  1. Studies of Exagamglogene Autotemcel - Age and Place.2024The New England journal of medicine

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 32 篇,占 11.8%。

牵头论文
32
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 6620222023: 7720232024: 5520242025: 552025

北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
    分期
    III期
    开始
    2024-04
    登记号
    NCT07437404

    年龄 未注明 至 6 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  2. 正在招募
    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
    分期
    III期
    开始
    2022-12
    登记号
    NCT05611801

    年龄 1 岁 至 17 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉

  3. 正在招募
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    分期
    III期
    开始
    2021-11
    登记号
    NCT05145127

    年龄 1 岁 至 74 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、广州、武汉、贵阳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文32
  1. Analysis of the current situation and influencing factors of home treatment for children with hemophilia in China.2025Annals of hematology
  2. The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study.2025Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  3. Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.2025Journal of thrombosis and haemostasis : JTH
  4. The Chinese Haemophilia Individualized Prophylaxis (CHIPS): A cost-effective regimen for zero joint bleeding and long-term joint health in boys with Severe Haemophilia A (SHA) on factor replacement.2025Thrombosis research
  5. A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973.2025Thrombosis research
  6. Surgical procedures and complications in placement of totally implantable venous access port in pediatric hemophilia patients: A retrospective analysis.2024Blood cells, molecules & diseases
  7. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China.2024Clinical therapeutics
  8. Oral health status and oral habits of children and adolescents with hemophilia: a report from the children's hemophilia comprehensive care center of China.2024European journal of pediatrics
  9. The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.2024Hematology (Amsterdam, Netherlands)
  10. A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS).2024Thrombosis research
  11. Successful treatment of Henoch-Schönlein purpura-associated hematochezia in a child with hemophilia A: a case report.2023BMC pediatrics
  12. Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China.2023Hematology (Amsterdam, Netherlands)
  13. Machine learning model for predicting physical activity related bleeding risk in Chinese boys with haemophilia A.2023Thrombosis research
  14. Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors.2023Thrombosis research
  15. Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes.2023Thrombosis research
  16. The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China.2023Thrombosis research
  17. The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China.2023Thrombosis research
  18. Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A.2022Haemophilia : the official journal of the World Federation of Hemophilia
  19. Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia.2022Haemophilia : the official journal of the World Federation of Hemophilia
  20. Altered brain activity and functional networks in school-age boys with severe haemophilia A: A resting-state functional magnetic resonance imaging study.2022Haemophilia : the official journal of the World Federation of Hemophilia
  21. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with rituximab-based immunosuppressive agent(s) in China.2022Haemophilia : the official journal of the World Federation of Hemophilia
  22. "A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates": Comment from Huang et al.2022Journal of thrombosis and haemostasis : JTH
  23. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A.2022Thrombosis research
  24. Pharmacokinetics and complementary evaluation system-based guidance on prophylaxis of paediatric patients with haemophilia A in China with Kovaltry: protocol of the LEAP study.2021BMJ open
  25. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.2021Clinical therapeutics
  26. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
  27. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.2021Haemophilia : the official journal of the World Federation of Hemophilia
  28. A low-dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high-titre factor VIII inhibitor and poor-ITI prognostic risk.2021Haemophilia : the official journal of the World Federation of Hemophilia
  29. Comparative pharmacokinetics of Kogenate FS and Kovaltry in 14 Chinese paediatric patients with haemophilia A: A single-centre study.2021Haemophilia : the official journal of the World Federation of Hemophilia
  30. Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient.2021International journal of immunopathology and pharmacology
  31. Generation of induced pluripotent stem cell, BCHSCTi001-A, derived from a Hemophilia A patient with F8 (p. R391C) mutation.2021Stem cell research
  32. Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A.2021The Journal of biological chemistry
中文论文(未计入)1
  1. [Clinical efficacy and safety of Octocog alfa in Chinese patients with hemophilia A: One-year follow-up results from the Antihemophilic Factor Hemophilia A Outcome Database (AHEAD) study].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
早期论文(2016–2020 年)14
  1. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.2020Haemophilia : the official journal of the World Federation of Hemophilia
  2. A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations.2020International journal of immunopathology and pharmacology
  3. Bleeds and imaging scoring scales in relation to pharmacokinetics of coagulation factor VIII in Chinese pediatric patients with severe hemophilia A.2020Thrombosis research
  4. Hemophilia Gene Therapy: New Development from Bench to Bed Side.2019Current gene therapy
  5. Common themes and challenges in hemophilia care: a multinational perspective.2019Hematology (Amsterdam, Netherlands)
  6. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.2018Chinese medical journal
  7. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.2018Haemophilia : the official journal of the World Federation of Hemophilia
  8. Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO-KLAT.2018Haemophilia : the official journal of the World Federation of Hemophilia
  9. [Analysis of the arthropathies on no-bleeding history joints in pre-school age severe hemophilia A children].2018Zhonghua er ke za zhi = Chinese journal of pediatrics
  10. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.2017Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  11. The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China.2017Expert review of hematology
  12. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.2017Haemophilia : the official journal of the World Federation of Hemophilia
  13. Preliminary evaluation of altered brain microstructure in the emotion-cognition region in children with haemophilia A: a diffusional kurtosis imaging study.2017Haemophilia : the official journal of the World Federation of Hemophilia
  14. [Analysis of individualized primary prophylactic treatment of 19 cases of children with severe hemophilia A].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
  1. Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China状态不明NCT03598725牵头方IV期2016-01 启动
  2. A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children状态不明NCT02999308牵头方IV期2016-08 启动
  3. Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.正在招募NCT07437404研究中心III期2024-04 启动
  4. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B正在招募NCT05611801研究中心III期2022-12 启动
  5. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors正在招募NCT05145127研究中心III期2021-11 启动
  6. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A即将招募NCT06136507研究中心III期2026-12 启动
  7. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products已完成NCT06738485研究中心III期2025-01 启动
  8. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  9. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A进行中,不再招募NCT05685238研究中心III期2023-02 启动
  10. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors已完成NCT05306418研究中心III期2022-04 启动
  11. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)已完成NCT05082116研究中心III期2021-09 启动
  12. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A已完成NCT04845399研究中心III期2021-04 启动
  13. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors已完成NCT05053139研究中心III期2021-12 启动
  14. A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for Injection已完成NCT05251090研究中心I期2021-06 启动
  15. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B已完成NCT03938792研究中心III期2020-03 启动
  16. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  17. A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A已完成NCT04565236研究中心IV期2020-09 启动
  18. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection状态不明NCT03747653研究中心2019-03 启动
  19. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants已完成NCT03315455研究中心III期2018-04 启动
  20. Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A已完成NCT02461992研究中心I期2015-07 启动
  21. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A已完成NCT02492984研究中心IV期2015-04 启动
  22. China ADVATE PTP Study已完成NCT02170402研究中心IV期2014-06 启动
  23. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)已完成NCT02078427研究中心2011-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 2 篇,占 7.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

北京有 6 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Analysis of five children with acquired thrombotic thrombocytopenic purpura].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
早期论文(2016–2020 年)1
  1. [Analysis of 5 children with congenital thrombotic thrombocytopenic purpura].2019Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura进行中,不再招募NCT04683003研究中心III期2021-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 3 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录
牵头的论文1
  1. A case of ADH5/ALDH2 deficiency combined with 3q29 microduplication syndrome.2025BMC pediatrics免费全文
中文论文(未计入)1
  1. [Progress in pathogenesis of bone marrow failure in Fanconi anemia].2022Zhonghua er ke za zhi = Chinese journal of pediatrics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断孕期、儿童与老人视神经与视力
论文中的科室眼科/神经眼科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

北京有 8 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流中风与出血儿童
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

胆道闭锁

Biliary atresia

2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 15 篇,占 7.0%。

牵头论文
15
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 6620222023: 3320232024: 1120242025: 222025

北京有 3 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。

这些数字背后的记录
研究主题筛查与诊断发病机制Kasai手术
论文中的科室普外/肝胆胰外科影像/核医学科
牵头的论文15
  1. S1P/S1PR4 promotes the differentiation of CD8+ tissue-resident memory T cells aggravating bile duct injury in biliary atresia.2026Journal of hepatology
  2. SULT2B1 promotes cholangiocyte epithelial-mesenchymal transition via Wnt/β-catenin/MMP7 pathway in biliary atresia.2026Pediatric research免费全文
  3. Is performing the Kasai portoenterostomy in the neonatal period associated with a better prognosis? A single-center, retrospective cohort study from China.2025BMC pediatrics免费全文
  4. Development and validation of a screening model for early diagnosis of biliary atresia in neonates with cholestasis.2025Pediatric surgery international
  5. Development of a diagnostic model for biliary atresia based on MMP7 and serological tests using machine learning.2024Pediatric surgery international
  6. Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA/S1PR2/ZBP1/p-MLKL axis.2023Cell death & disease免费全文
  7. Laparoscopic indocyanine green fluorescence imaging technique in rare type II cystic biliary atresia.2023Photodiagnosis and photodynamic therapy
  8. Preliminary exploration of the efficacy of laparoscopic fluorescence cholangiography (LFC) in the diagnosis of biliary atresia compared with intraoperative cholangiography (IOC).2023Photodiagnosis and photodynamic therapy
  9. Development and validation of a novel nomogram and risk score for biliary atresia in patients with cholestasis.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  10. The utility of shear wave elastography and serum biomarkers for diagnosing biliary atresia and predicting clinical outcomes.2022European journal of pediatrics
  11. Comprehensive Analysis of Gut Microbiota and Fecal Bile Acid Profiles in Children With Biliary Atresia.2022Frontiers in cellular and infection microbiology免费全文
  12. Identifying and validating molecular subtypes of biliary atresia using multiple high-throughput data integration analysis.2022Frontiers in immunology免费全文
  13. Diagnosis of liver cirrhosis with two-dimensional shear wave elastography in biliary atresia before Kasai portoenterostomy.2022Pediatric surgery international
  14. Exploratory application of indocyanine green quantification in biliary atresia observational study.2022Photodiagnosis and photodynamic therapy
  15. Development and Validation of a Nomogram Incorporating Ultrasonic and Elastic Findings for the Preoperative Diagnosis of Biliary Atresia.2021Academic radiology
PubMed 以外找到的论文(未计入)4
  1. A Transfer Learning-Based Diagnostic Model for Biliary Atresia: A Multicenter Study with 389 Cases2025Research Square预印本
  2. IDDF2024-ABS-0207 S1P/S1PR4 promotes the differentiation of CD8+TRM cells aggravating bile duct injury in biliary atresia2024Gut会议论文
  3. IDDF2024-ABS-0285 Ferritinophagy activation and sideroflexin3-dependent mitochondrial iron overload contribute to biliary epithelial cells epithelial-mesenchymal transition and liver fibrosis in biliary atresia2024Gut会议论文
  4. IDDF2024-ABS-0308 YQHX inhibits hepatic stellate cells activation by suppressing NCOA4-mediated ferritinophagy in biliary atresia2024Gut会议论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 0020232024: 1120242025: 002025

北京有 13 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文4
  1. Autoimmune Basal Ganglia Encephalitis Associated With Anti-N-methyl-d-Aspartate Receptor Antibodies in Children.2024Pediatric neurology
  2. Pediatric anti-N-methyl-D-aspartate receptor encephalitis with MOG-Ab co-existence: Relapse propensity and treatability.2022Multiple sclerosis and related disorders
  3. Age-dependent characteristics and prognostic factors of pediatric anti-N-methyl-d-aspartate receptor encephalitis in a Chinese single-center study.2021European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  4. Clinical Features and Outcomes of Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Infants and Toddlers.2021Pediatric neurology
中文论文(未计入)1
  1. [Risk factors and prognosis of anti-N-methyl-D-aspartate receptor encephalitis following herpes simplex virus encephalitis in children].2025Zhonghua er ke za zhi = Chinese journal of pediatrics
早期论文(2016–2020 年)2
  1. [Clinical observation on the overlapping syndrome of myelin oligodendrocyte glycoprotein antibody and anti-N-methyl-D aspartate receptor in children].2020Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Clinical and electroencephalographic analysis of anti-N-methyl-D-aspartate receptor encephalitis in children].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis进行中,不再招募NCT05503264研究中心III期2022-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 0020242025: 002025

北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 8 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
    分期
    III期
    开始
    2025-05
    登记号
    NCT06971094

    年龄 2 岁 至 12 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、武汉、深圳、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III正在招募NCT06971094研究中心III期2025-05 启动
  2. Pediatric Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05042921研究中心2021-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 11 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Fabry Aim Children Early (ACE) Project已撤回NCT04965467研究中心2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

北京有 11 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 7 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室肾内科耳鼻喉/头颈外科
牵头的论文1
  1. Alport syndrome complicated with steroid-sensitive nephrotic syndrome: a case report.2025Pediatric nephrology (Berlin, Germany)
中文论文(未计入)1
  1. [Long-term auditory monitoring in children with Alport syndrome based on different degrees of renal injury].2024Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.9%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 3320232024: 1120242025: 002025

北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科病理/检验科
牵头的论文7
  1. Predictive role of Oxford Classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis.2024Renal failure
  2. Long noncoding RNA FGD5-AS1 alleviates childhood IgA nephropathy by targeting PTEN-mediated JNK/c-Jun signaling pathway via miR-196b-5p.2023Experimental cell research
  3. Clinical relevance of glomerular C4d deposition in children with early IgA nephropathy or Henoch-Schönlein purpura nephropathy.2023Pediatric nephrology (Berlin, Germany)
  4. Characteristics of children with IgA nephropathy.2023Pediatric research
  5. Contrast-enhanced ultrasonography for assessing histopathology in pediatric immunoglobulin A nephropathy and Henoch-Schönlein purpura nephritis.2022Pediatric radiology
  6. Mesangial C3 deposition and serum C3 levels predict renal outcome in IgA nephropathy.2021Clinical and experimental nephrology
  7. Serum levels of galactose-deficient IgA1 in Chinese children with IgA nephropathy, IgA vasculitis with nephritis, and IgA vasculitis.2021Clinical and experimental nephrology
中文论文(未计入)1
  1. [Hemolytic uremic syndrome complicated with IgA nephropathy: a clinicopathological study].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
早期论文(2016–2020 年)5
  1. MicroRNA‑196b targets COSMC in pediatric IgA nephropathy.2020Molecular medicine reports
  2. The Characteristics of Intestinal-Barrier Damage in Rats With IgA Nephropathy.2020The American journal of the medical sciences
  3. A clinicopathological comparison between IgA nephropathy and Henoch-Schönlein purpura nephritis in children: use of the Oxford classification.2019Clinical and experimental nephrology
  4. [Role of IgG antibody to galactose-deficient IgA1 in children with IgA nephropathy].2017Zhonghua er ke za zhi = Chinese journal of pediatrics
  5. Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.2016PloS one

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 5 家医院列在戈谢病下全国有 41 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 13 篇,占 8.1%。

牵头论文
13
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 4420222023: 1120232024: 2220242025: 332025

北京有 8 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文13
  1. Total Transanal Endorectal Pull-through Versus Laparoscopic-Assisted Approach in Children with Rectosigmoid Hirschsprung's Disease: A Systematic Review and Meta-Analysis.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  2. Risk factors for Hirschsprung's disease in infancy: A study from the NHANES database.2025Medicine
  3. Risk factors of bowel perforation in neonates with Hirschsprung disease.2025Pediatric surgery international
  4. Surgical outcomes for patients with rectosigmoid hirschsprung disease who underwent transanal endorectal pull-through after 1 year of age.2024BMC surgery
  5. Bowel perforation in neonates with Hirschsprung disease: a case series and literature review.2024Pediatric surgery international
  6. Long-term bowel function after single-stage transanal endorectal pull-through in neonatal patients with Hirschsprung disease.2023Pediatric surgery international
  7. Risk factors for Hirschsprung-associated enterocolitis following Soave: a retrospective study over a decade.2022BMC pediatrics
  8. Risk factors of enterostomy in neonates with Hirschsprung disease.2022International journal of colorectal disease
  9. Three dimension high-definition manometry in evaluation of anorectal function in 104 normal infants and children: A clinical study from China.2022Neurogastroenterology and motility
  10. One-stage transanal endorectal pull-through for Hirschsprung disease: experience with 229 neonates.2022Pediatric surgery international
  11. Redo Transanal Soave Pull Through with or without Assistance in Hirschsprung Disease: An Experience in 46 Patients.2021European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie
  12. Rectourethral and rectovesical fistula as serious and rare complications after Hirschsprung disease operation: Experience in seven patients.2021Journal of pediatric surgery
  13. Vascular Malformation of the Colorectum in Children: Case Series of 27 Patients.2021World journal of surgery
早期论文(2016–2020 年)3
  1. Barium enema findings in total colonic aganglionosis: a single-center, retrospective study.2020BMC pediatrics
  2. Clinical Outcomes After Staged and Primary Laparotomy Soave Procedure for Total Colonic Aganglionosis: a Single-Center Experience from 2007 to 2017.2020Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  3. STROBE-anastomotic leakage after pull-through procedure for Hirschsprung disease.2018Medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 4 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Majeed 综合征

Majeed syndrome

2021–2025 年没有牵头Majeed 综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 2 家医院列在Majeed 综合征下全国有 7 家医院列在Majeed 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Majeed 综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

首都医科大学附属北京儿童医院

Beijing Children's Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Beijing Children Hospital; Beijing Children's Hospital Affiliated to Capital Medical University; Beijing Children's Hospital Affiliated With Capital Medical University; BeiJing Children's Hospital; Ministry of Education Beijing Children's Hospital; Xinjiang Hospital of Beijing Children's Hospital; Affiliated Beijing Children's Hospital; Beijing Children’s Hospital

提出更正下载数据